National Cancer Center

Singapore 169610

0 studies enrolling now · 5 studies all time

What they study most

ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC, Antimetabolites, Antineoplastic, Digestive System Diseases, Digestive System Neoplasms, Endocrine Gland Neoplasms, Endocrine System Diseases, Gemcitabine, Hematologic Malignancies, Myelodysplastic Syndrome, Nasopharyngeal Neoplasms, Neoplasms, Neoplasms by Site

Studies at this site

• A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations — Completed
• Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) — Completed
• Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma — Completed
• A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS) — Completed
• A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine — Completed